Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Authors
Keywords
-
Journal
THYROID
Volume -, Issue -, Pages -
Publisher
Mary Ann Liebert Inc
Online
2022-04-21
DOI
10.1089/thy.2022.0054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
- (2021) Xiangqian Zheng et al. CLINICAL CANCER RESEARCH
- Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Marcia S Brose et al. LANCET ONCOLOGY
- A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
- (2021) Marcia S Brose et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
- (2020) Eyun Song et al. THYROID
- Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
- (2020) Jonathan K. Kish et al. ADVANCES IN THERAPY
- Real world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer
- (2020) Viktoria Koehler et al. THYROID
- A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer
- (2019) Shunji Takahashi et al. Future Oncology
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- (2019) Soo Young Kim et al. Frontiers in Endocrinology
- Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data
- (2019) Mehtap Derya Aydemirli et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
- (2019) Hye-Seon Oh et al. THYROID
- A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
- (2019) Nigel Fleeman et al. BMC CANCER
- Prolonged duration of response in lenvatinib responders with thyroid cancer
- (2018) Andrew G Gianoukakis et al. ENDOCRINE-RELATED CANCER
- Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice
- (2018) Amandine Berdelou et al. THYROID
- Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
- (2018) Mijin Kim et al. THYROID
- Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer
- (2018) Makoto Tahara et al. EUROPEAN JOURNAL OF CANCER
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer
- (2015) Naomi Kiyota et al. CANCER SCIENCE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network
- (2014) Marie-Hélène Massicotte et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
- (2014) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- (2014) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started